Prohost Letter #394 Part 1
Gilead - Some people sold Gilead’s (GILD) stock on Wednesday, March 23 after news announced on Tuesday that a jury decided that Gilead has infringed on two HCV molecules patents that Ionis (IONS), formerly Isis, and Merck had secured from their research. Ionis CEO said in a press release that his firm and Merck used their expertise during their collaboration in 1998 to discover and develop modified nucleosides that benefit patients with HCV.
In 2013, Merck asked for a 10% royalty on sales from Gilead. Gilead demanded . . .
This content is for paid subscribers.
Prohost Letters April 1, 2016